Genmab As (GMAB) SEC Filing 6-K Foreign Issuer Report for the period ending Monday, November 21, 2022

Genmab As

CIK: 1434265 Ticker: GMAB

View differences made from one to another to evaluate Genmab As's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Genmab As.


Assess how Genmab As's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Genmab As's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Genmab As provided additional information to their SEC Filing as exhibits

Ticker: GMAB
CIK: 1434265
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001558370-22-018125
Submitted to the SEC: Mon Nov 21 2022 2:55:01 PM EST
Accepted by the SEC: Mon Nov 21 2022
Period: Monday, November 21, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: